These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
7. Proteomics of a conundrum: Thoughts on addressing the aetiology versus progression of multiple sclerosis. Partridge MA; Myers SJ; Gopinath S; Coorssen JR Proteomics Clin Appl; 2015 Oct; 9(9-10):838-43. PubMed ID: 25580822 [TBL] [Abstract][Full Text] [Related]
8. Proteomics in Multiple Sclerosis: The Perspective of the Clinician. Sandi D; Kokas Z; Biernacki T; Bencsik K; Klivényi P; Vécsei L Int J Mol Sci; 2022 May; 23(9):. PubMed ID: 35563559 [TBL] [Abstract][Full Text] [Related]
9. [Recent advances in pathogenesis and therapy of multiple sclerosis]. Linker RA; Stadelmann C; Diem R; Bähr M; Brück W; Gold R Fortschr Neurol Psychiatr; 2005 Dec; 73(12):715-27. PubMed ID: 16355314 [TBL] [Abstract][Full Text] [Related]
10. From classic to spontaneous and humanized models of multiple sclerosis: impact on understanding pathogenesis and drug development. Ben-Nun A; Kaushansky N; Kawakami N; Krishnamoorthy G; Berer K; Liblau R; Hohlfeld R; Wekerle H J Autoimmun; 2014 Nov; 54():33-50. PubMed ID: 25175979 [TBL] [Abstract][Full Text] [Related]
11. Application of quantitative proteomics technologies to the biomarker discovery pipeline for multiple sclerosis. Dagley LF; Emili A; Purcell AW Proteomics Clin Appl; 2013 Jan; 7(1-2):91-108. PubMed ID: 23112123 [TBL] [Abstract][Full Text] [Related]
12. New findings and old controversies in the research of multiple sclerosis and its model experimental autoimmune encephalomyelitis. Aharoni R Expert Rev Clin Immunol; 2013 May; 9(5):423-40. PubMed ID: 23634737 [TBL] [Abstract][Full Text] [Related]
14. [Experimental allergic encephalomyelitis as an animal model for multiple sclerosis]. Lukinović-Skudar V; Taradi SK; Andreis I; Zupancić V; Taradi M Lijec Vjesn; 2001; 123(3-4):81-8. PubMed ID: 11488222 [TBL] [Abstract][Full Text] [Related]
15. Proteomics of human cerebrospinal fluid: discovery and verification of biomarker candidates in neurodegenerative diseases using quantitative proteomics. Kroksveen AC; Opsahl JA; Aye TT; Ulvik RJ; Berven FS J Proteomics; 2011 Apr; 74(4):371-88. PubMed ID: 21111852 [TBL] [Abstract][Full Text] [Related]
16. The experimental autoimmune encephalomyelitis model for proteomic biomarker studies: from rat to human. Rosenling T; Attali A; Luider TM; Bischoff R Clin Chim Acta; 2011 May; 412(11-12):812-22. PubMed ID: 21333641 [TBL] [Abstract][Full Text] [Related]
17. Proteomics Approach to Identify Biomarkers in Neurodegenerative Diseases. Nayak A; Salt G; Verma SK; Kishore U Int Rev Neurobiol; 2015; 121():59-86. PubMed ID: 26315762 [TBL] [Abstract][Full Text] [Related]
18. Multiple sclerosis and chronic autoimmune encephalomyelitis: a comparative quantitative study of axonal injury in active, inactive, and remyelinated lesions. Kornek B; Storch MK; Weissert R; Wallstroem E; Stefferl A; Olsson T; Linington C; Schmidbauer M; Lassmann H Am J Pathol; 2000 Jul; 157(1):267-76. PubMed ID: 10880396 [TBL] [Abstract][Full Text] [Related]
19. Proteinase-activated receptor 2 modulates neuroinflammation in experimental autoimmune encephalomyelitis and multiple sclerosis. Noorbakhsh F; Tsutsui S; Vergnolle N; Boven LA; Shariat N; Vodjgani M; Warren KG; Andrade-Gordon P; Hollenberg MD; Power C J Exp Med; 2006 Feb; 203(2):425-35. PubMed ID: 16476770 [TBL] [Abstract][Full Text] [Related]
20. Essential fatty acids and related molecular and cellular mechanisms in multiple sclerosis: new looks at old concepts. Mayer M Folia Biol (Praha); 1999; 45(4):133-41. PubMed ID: 10732726 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]